Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Uni Eropa - Kroasia - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za više informacija, molimo pogledajte odjeljak 5.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Uni Eropa - Kroasia - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Tenofovirdizoproksil Pliva 245 mg filmom obložene tablete Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

tenofovirdizoproksil pliva 245 mg filmom obložene tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - tenofovirdizoproksilfumarat - filmom obložena tableta - 245 mg - urbroj: jedna filmom obložena tableta sadrži 245 mg tenofovirdizoproksila (u obliku fumarata)

Abelcet lipid complex 5 mg/ml koncentrat za disperziju za infuziju Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

abelcet lipid complex 5 mg/ml koncentrat za disperziju za infuziju

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - amfotericin b - koncentrat za disperziju za infuziju - 5 mg/ml - urbroj: 1 ml koncentrata za disperziju sadrži 5 mg amfotericina b

TENOFOVIR TEVA 245 mg/1 tableta filmom obložena tableta Bosnia dan Herzegovina - Kroasia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tenofovir teva 245 mg/1 tableta filmom obložena tableta

pliva d.o.o.sarajevo - Тенофовир disoproksil - filmom obložena tableta - 245 mg/1 tableta - jedna filmom obložena tableta sadrži: 245 mg tenofovir disoproksila u obliku fumarata

Xiliarx Uni Eropa - Kroasia - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Brukinsa Uni Eropa - Kroasia - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

TRACTOCILE 7.5 mg/1 mL koncentrat za rastvor za infuziju Bosnia dan Herzegovina - Kroasia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tractocile 7.5 mg/1 ml koncentrat za rastvor za infuziju

clinres farmacija d.o.o. - atosiban - koncentrat za rastvor za infuziju - 7.5 mg/1 ml - 5 ml koncentrata za rastvor za infuziju sadrži: 37,5 mg (7,5 mg/ml) atosiban (u obliku atosiban acetata)

TRACTOCILE 7.5 mg/1 mL rastvor za injekciju Bosnia dan Herzegovina - Kroasia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tractocile 7.5 mg/1 ml rastvor za injekciju

clinres farmacija d.o.o. - atosiban - rastvor za injekciju - 7.5 mg/1 ml - 0,9 ml rastvora za injekciju sadrži: 6,75 mg (7,5 mg/ml) atosibana (u obliku atosiban acetata)

TACFORIUS 0,5 mg/1 kapsula kapsula s produljenim oslobađanjem, tvrda Bosnia dan Herzegovina - Kroasia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tacforius 0,5 mg/1 kapsula kapsula s produljenim oslobađanjem, tvrda

pliva d.o.o.sarajevo - tacrolimus - kapsula s produljenim oslobađanjem, tvrda - 0,5 mg/1 kapsula - 1 kapsula s produljenim oslobađanjem, tvrda sadrž: 0,5 mg takrolimusa (u obliku hidrata).